903129-78-2

Basic information

• Product Name: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID
• Synonyms: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID;6-bromo-1H-imidazo[1,2-a]pyridine-8-carboxylic acid;6-bromo-1H-imidazo[1,2-a]...;2-a]pyridine-8-carboxylic acid;6-broMoH-iMidazo[1;IMidazo[1,2-a]pyridine-8-carboxylic acid, 6-broMo-
• CAS NO: 903129-78-2
• Molecular Formula: C₈H₅BrN₂O₂
• Molecular Weight: 241.04
• Mol File: 903129-78-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.899 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1.37±0.41(Predicted)
• CAS DataBase Reference: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID(903129-78-2)
• EPA Substance Registry System: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID(903129-78-2)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• Hazardous Substances Data: 903129-78-2(Hazardous Substances Data)

Usage

General Description

6-Bromo-imidazo[1,2-a]pyridine-8-carboxylic acid is a chemical compound with the molecular formula C8H5BrN2O2. It is a heterocyclic compound that contains a pyridine ring and an imidazole ring, with a carboxylic acid group attached at the 8 position of the pyridine ring. 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-8-CARBOXYLIC ACID is commonly used in medicinal and pharmaceutical research as a building block for the synthesis of various biologically active molecules, such as antiviral and antibacterial agents. It may also have potential applications in the development of new drugs for the treatment of various diseases and conditions.

Upstream product

• 107-20-0 2-chloroethanal 
• 52833-94-0 2-amino-5-bromonicotinicacid 
• 97-97-2 chloroacetaldehyde dimethyl acetal 

Relevant articles and documents

Discovery of [1,2,4]Triazolo[4,3- a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction using small-molecule inhibitors is an emerging immunotherapeutic approach. A novel series of [1,2,4]triazolo[4,3-a]pyridines were designed and found to be potent inhibitors of the PD-1/PD-L1 interaction. Among them, compound A22 exhibited the most potent activity, as assessed by homogenous time-resolved fluorescence assay, with an IC50 of 92.3 nM. Furthermore, A22 dose-dependent elevated interferon-γproduction in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. We concluded that A22 is a promising lead compound for the development of inhibitors of the PD-1/PD-L1 interaction. In addition, we explored the structure-activity relationships of the newly synthesized [1,2,4]triazolo[4,3-a]pyridines and demonstrated that a ring fusion strategy can be employed for designing analogues of the Bristol-Myers Squibb chemical series. These studies pave the way for future drug design.

IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

rmidazo[l,2-α]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic- related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.